



# SIGHTGLASS VISION

## SightGlass Vision Reports Positive Four-Year Clinical Trial Outcomes for Myopia Control DOT Spectacle Lenses

*Compelling Axial Length and cSER Findings, Plus New Case Reviews from Chinese Children,  
Presented at the 27<sup>th</sup> Congress of the Chinese Ophthalmological Society*

**CHANGSHA, China, September 6, 2023**—[SightGlass Vision](#) today reported positive four-year outcomes from its pivotal CYPRESS study extension, which is evaluating the myopia control performance of the company's [Diffusion Optics Technology™ \(DOT 0.2\) spectacle lenses](#). The lenses use thousands of light scattering elements called dots, designed to mimic more natural contrast on the retina—a unique mechanism of action to slow myopia progression in children.

The findings are being presented at the 27th Congress of the Chinese Ophthalmological Society (CCOS), held in Changsha, Hunan Province. Thousands of eye care clinicians, researchers, and educators from across China and overseas attend the biennial event.

***Control of Myopia using Diffusion Optics Technology Spectacle Lenses: Efficacy and Safety Study (CYPRESS) 4 Year Results (Zhu X, McParland M, et al)*** affirmed DOT 0.2 safety and efficacy in children aged 6–10 at the study's initiation [1]. Part two of the study—designed to collect 12 additional months of data—re-enrolled 98 participants from the original three-year, double-masked, randomized, multi-site clinical trial.

Full four-year outcomes showed statistically significant slowing of axial length progression and cycloplegic spherical equivalent refraction (cSER), with the most recent data underscoring strong DOT 0.2 performance. During the 36- to 48-month timeframe, axial length mean change was  $0.13 \pm 0.02$  mm for the test group (n=55) and  $0.18 \pm 0.02$  mm for the control (n=41; p=0.038). cSER mean change was  $-0.25 \pm 0.04$  D for the test group and  $-0.38 \pm 0.05$  D for control (p=0.043).

“The CYPRESS four-year findings confirm the demonstrated efficacy, safety, and overall performance of Diffusion Optics Technology™ spectacle lenses,” said Andrew Sedgwick, CEO of SightGlass Vision. “Eye care professionals worldwide are demanding this level of scientific rigor, allowing them to confidently recommend the lenses to children and their caregivers. SightGlass Vision is proud to advance the myopia control category with our

latest research and technologies, and enthusiastic about growing opportunities for spectacles in a child's treatment regimen.”

A separate presentation at CCOS explored the theoretical basis and practical application of DOT lenses. ***Discussion of DOT Lenses Based on Contrast Reduction Theory and Real-World Case Sharing (Wang D, Xie P, Huang J)*** analyzed the influence of contrast in children's refractive development, the interaction between contrast signals and peripheral defocus signals, and the clinical performance of DOT lenses based on contrast reduction. Comparing existing studies with clinical observations of 117 Chinese children wearing DOT 0.2 lenses for 1 year, investigators concluded that contrast management delayed myopia progression, and that the lenses were effective and safe.

Over the last two years, SightGlass Vision's patent-protected technology with clinically proven efficacy [1,2,3,4] made its commercial debut in several markets, including China, the Netherlands, and Israel, as well as through preliminary market trials in other countries. The company operates as a joint venture of [CooperCompanies](#) and [EssilorLuxottica](#).

For more information, visit [SightGlassVision.com](#).

#### **About SightGlass Vision**

SightGlass Vision develops innovative technologies and science-based treatments to address the global myopia epidemic, backed by novel and comprehensive research. Its unique Diffusion Optics Technology™ is based on ground-breaking discoveries surrounding myopia progression. Spectacle lenses using its patent-protected approach incorporate thousands of light scattering elements called dots designed to mimic more natural contrast on the retina—a method intended to reduce myopia progression in children. The treatment has completed the three years pivotal multisite clinical study. Founded in 2016, the company now operates as a joint venture of CooperCompanies and EssilorLuxottica to accelerate commercialization opportunities and expand the myopia management category worldwide.

*SightGlass Vision™ Diffusion Optics Technology™ spectacle lenses are not available for sale in the United States.*

#### **Media Contact**

Mike McDougall, APR, Fellow PRSA, FAAO  
McDougall Communications for SightGlass Vision  
+1-585-545-1815 or [mike@mcdougallpr.com](mailto:mike@mcdougallpr.com)







---

<sup>1</sup> Chalberg T., et al. Control of Myopia Using Diffusion Optics Spectacle Lenses: Efficacy and Safety Study (CYPRESS) 42-month results. ARVO 2023 Annual Meeting presentation. 27 April 2023.

<sup>2</sup> Control of myopia using Diffusion Optics Technology™ spectacle lenses: 12-month results of a randomised controlled, efficacy and safety study (CYPRESS). British Journal of Ophthalmology Published Online First: 01 September 2022. DOI: 10.1136/bjo-2021-321005

<sup>3</sup> Rappon J., et al. Two-year effectiveness of a novel myopia management spectacle lens with full-time WEARERS. Invest. Ophthalmol. Vis. Sci. 2022;63(7):408.

<sup>4</sup> Laughton, D et al. Safety and Efficacy of a Novel Spectacle Lens for Myopia Control Over Three Years. 2022 American Academy of Optometry annual meeting. 27 Oct 2022.